News and Press Releases

Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611

14 October 2025 -- Paris, France -- PulseSight Therapeutics, a clinical stage ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology welcomes the publication of new data...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

SeaBeLife secures €2 million

This funding will help fast-track the launch of clinical trials in dry AMD and severe acute hepatitis programs 1 October 2025 -- Roscoff, France -- SeaBeLife, a biotechnology company developing...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 1, 2025

Place Georges Teissier 29680 ROSCOFF

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months. 6 May 2025...

Category: Biotechnology, Clinical Trials, Drug Discovery, Logistics, Other, Pharmaceutical
Posted: May 6, 2025

14193 NW 119th Terrace,
 Suite #20,
 Alachua, Florida 32615, US

Eleva Publishes Evidence of Immunomodulation and Neuroprotection Using its Factor H Biological Therapy in Preclinical Dry AMD Study

Eleva confirms dry AMD as second indication for proprietary Factor H (CPV-104) program 15 April 2025 -- Freiburg im Breisgau, Germany -- Eleva, a pioneer in discovering and developing previously...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2025

Hans-Bunte-Str. 19 79108 Freiburg Germany